Background
Vaccine and cure regimens aiming to induce HIV-1 neutralizing antibodies (nAb) in people living with HIV-1 (PLWH) will benefit from a better understanding of the dynamics and durability of nAb during ART and reliable assay platforms to assess them.
Methods
We analyzed plasma and PBMC samples from 15 ACTG A5257 participants (median 40 years, 87% male, 33% Black, median pre-ART CD4 361 cells/mm³), initiated on ART at US sites. Longitudinal samples were collected pre-ART and at 1, 3 and ≥4 years during long-term ART suppression. To enable neutralization testing on ART, plasma IgG was purified with efficiency measured by spiked SIV mAb K11. IgG was reconstituted to the original plasma volume. Autologous pseudovirus stocks were prepared from Env expression vectors derived from pre-ART plasma and on-ART PBMC. Autologous nAb were quantified using the PhenoSense nAb assay platform. Heterologous nAb were measured against a 9-virus global reference panel. Results are expressed as the IgG dilution that neutralized 50% of each pseudovirus stock (ID50); ID50 >20 was considered a detectable response.
Results
Heterologous nAb responses to at least one virus were detected pre-ART in 9/15 participants (60%) vs 2/15 (13%) at ART year 3 (p=0.02) (Figure Panel A). Responses generally declined with ART, then remained stable. After 3 years on ART, no new heterologous responses were detected, and ID50 titers declined or remained stable within 3-fold assay variability. 13/15 (87%) participants had detectable autologous nAb responses to their pre-ART plasma pseudoviruses; detectable nAb titers ranged from 21-92. 13/15 (87%) also neutralized their autologous PBMC-derived viruses at 3 years on ART, with a median change after 3 years on ART of 0.76-fold (≈24% reduction) (≈15%/year reduction) and no >3-fold increases detected (Figure Panel B).
Conclusions
In PLWH, heterologous nAb are low-titer pre-ART and decline after ART initiation. Autologous nAb titers against PBMC provirus are readily detectable in most PLWH and decline gradually with ART. These results inform our understanding of HIV-specific nAb dynamics in PLWH before and during ART. They also delineate baseline levels of heterologous and autologous nAb in PLWH on ART, and support the use of these assays to measure within-participant vaccine- or immunotherapy-induced increases in HIV-1 nAb responses.
Table or Figure
